Näytä suppeat kuvailutiedot

dc.contributor.authorHärkönen, Jouni
dc.contributor.authorPölönen, Petri
dc.contributor.authorJawahar Deen, Ashik
dc.contributor.authorSelvarajan, Ilakya
dc.contributor.authorTeppo, Hanna-Riikka
dc.contributor.authorDimova, Elitsa Y.
dc.contributor.authorKietzmann, Thomas
dc.contributor.authorAhtiainen, Maarit
dc.contributor.authorVäyrynen, Juha P.
dc.contributor.authorVäyrynen, Sara A.
dc.contributor.authorElomaa, Hanna
dc.contributor.authorTynkkynen, Niko
dc.contributor.authorEklund, Tiia
dc.contributor.authorKuopio, Teijo
dc.contributor.authorTalvitie, Eva-Maria
dc.contributor.authorTaimen, Pekka
dc.contributor.authorKallajoki, Markku
dc.contributor.authorKaikkonen, Minna, U.
dc.contributor.authorHeinäniemi, Merja
dc.contributor.authorLevonen, Anna-Liisa
dc.date.accessioned2023-03-13T12:54:25Z
dc.date.available2023-03-13T12:54:25Z
dc.date.issued2023
dc.identifier.citationHärkönen, J., Pölönen, P., Jawahar Deen, A., Selvarajan, I., Teppo, H.-R., Dimova, E. Y., Kietzmann, T., Ahtiainen, M., Väyrynen, J. P., Väyrynen, S. A., Elomaa, H., Tynkkynen, N., Eklund, T., Kuopio, T., Talvitie, E.-M., Taimen, P., Kallajoki, M., Kaikkonen, M., Heinäniemi, M., & Levonen, A.-L. (2023). A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies. <i>Redox Biology</i>, <i>61</i>, Article 102644. <a href="https://doi.org/10.1016/j.redox.2023.102644" target="_blank">https://doi.org/10.1016/j.redox.2023.102644</a>
dc.identifier.otherCONVID_177158565
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/85978
dc.description.abstractThe NRF2 pathway is frequently activated in various cancer types, yet a comprehensive analysis of its effects across different malignancies is currently lacking. We developed a NRF2 activity metric and utilized it to conduct a pan-cancer analysis of oncogenic NRF2 signaling. We identified an immunoevasive phenotype where high NRF2 activity is associated with low interferon-gamma (IFNγ), HLA-I expression and T cell and macrophage infiltration in squamous malignancies of the lung, head and neck area, cervix and esophagus. Squamous NRF2 overactive tumors comprise a molecular phenotype with SOX2/TP63 amplification, TP53 mutation and CDKN2A loss. These immune cold NRF2 hyperactive diseases are associated with upregulation of immunomodulatory NAMPT, WNT5A, SPP1, SLC7A11, SLC2A1 and PD-L1. Based on our functional genomics analyses, these genes represent candidate NRF2 targets, suggesting direct modulation of the tumor immune milieu. Single-cell mRNA data shows that cancer cells of this subtype exhibit decreased expression of IFNγ responsive ligands, and increased expression of immunosuppressive ligands NAMPT, SPP1 and WNT5A that mediate signaling in intercellular crosstalk. In addition, we discovered that the negative relationship of NRF2 and immune cells are explained by stromal populations of lung squamous cell carcinoma, and this effect spans multiple squamous malignancies based on our molecular subtyping and deconvolution data.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesRedox Biology
dc.rightsCC BY-NC-ND 4.0
dc.subject.otherNRF2
dc.subject.otherKEAP1
dc.subject.otherRedox
dc.subject.otherSquamous
dc.subject.otherT cells
dc.subject.otherInterferon gamma
dc.subject.otherHLA-I
dc.subject.otherSOX2
dc.subject.otherTP63
dc.subject.otherPD-L1
dc.titleA pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies
dc.typeresearch article
dc.identifier.urnURN:NBN:fi:jyu-202303132132
dc.contributor.laitosBio- ja ympäristötieteiden laitosfi
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosDepartment of Biological and Environmental Scienceen
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.oppiaineSolu- ja molekyylibiologiafi
dc.contributor.oppiaineGerontologian tutkimuskeskusfi
dc.contributor.oppiaineHyvinvoinnin tutkimuksen yhteisöfi
dc.contributor.oppiaineCell and Molecular Biologyen
dc.contributor.oppiaineGerontology Research Centeren
dc.contributor.oppiaineSchool of Wellbeingen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.relation.issn2213-2317
dc.relation.volume61
dc.type.versionpublishedVersion
dc.rights.copyright© 2023 The Authors. Published by Elsevier B.V.
dc.rights.accesslevelopenAccessfi
dc.type.publicationarticle
dc.subject.ysoT-imusolut
dc.subject.ysointerferonit
dc.subject.ysosoluviestintä
dc.subject.ysosyöpäsolut
dc.subject.ysotranskriptiotekijät
dc.subject.ysoimmuunivaste
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p38968
jyx.subject.urihttp://www.yso.fi/onto/yso/p8489
jyx.subject.urihttp://www.yso.fi/onto/yso/p28740
jyx.subject.urihttp://www.yso.fi/onto/yso/p23898
jyx.subject.urihttp://www.yso.fi/onto/yso/p28385
jyx.subject.urihttp://www.yso.fi/onto/yso/p21599
dc.rights.urlhttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.relation.doi10.1016/j.redox.2023.102644
jyx.fundinginformationThis study was supported by University of Eastern Finland Doctoral Program in Molecular Medicine, Finnish Cancer Foundation, The Academy of Finland (Grant number 332697), Sigrid Juselius Foundation, Paavo Koistinen Foundation (AL.L. lab) and Aatos Erkko Foundation (Grant number 210013) (T.K. lab). The study benefited from samples from Auria Biopankki Turku, Finland, and Central Finland Biobank, Jyväskylä, Finland.
dc.type.okmA1


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot

CC BY-NC-ND 4.0
Ellei muuten mainita, aineiston lisenssi on CC BY-NC-ND 4.0